BOSTON– Parthenon Therapeutics, a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME), today announced the appointment of Joseph Paul Eder, MD, as Chief Medical Officer.
“We are excited to welcome Dr. Joseph Paul Eder to Parthenon as Chief Medical Officer. Dr. Eder joins us at an important time in the growth of Parthenon, as we prepare to advance our lead drug candidate, PRTH-101, into the clinic, advance our clinical strategy, and continue to scale our pipeline of first-in-class therapeutics,” said Laurent Audoly, Ph.D, co-founder, Chief Executive Officer, and Chairman of the Board of Directors, Parthenon Therapeutics. “Parthenon is focused on advancing the right drug for the right patient. Our focus on precision medicine requires the seamless integration of insights into our mechanistic hypothesis, biomarker deployment, and clinical development. This is exemplified through Dr. Eder’s record of accomplishment in the development of anti-cancer therapeutics, most recently as Clinical Director at Yale Unversity’s Cancer Center. Dr. Eder has excelled in areas such as autologous bone transplant, modulation and reversal of drug resistance, cell cycle inhibitors, and the therapeutic use of anti-angiogenesis agents. His experience also extends to the pharmaceutical industry where he was Senior Medical Science Director & Global Clinical Medical Director, Hematology at AstraZeneca, PLC.”
“As member of Parthenon’s Clinical Advisory Board, I was impressed by the potential of the company’s unique approach, which can modulate the tumor microenvironment thereby making tumors shrink and become more susceptible to immune attack across a number of preclinical models,” said Dr. Eder. “This approach opens the door to an entirely new approach to treat immune-excluded tumors, either as a single agent or in combination with checkpoint inhibitors and beyond, and ultimately extending and improving the lives of cancer patients. As Chief Medical Officer, I look forward to working with the Parthenon team and our outstanding Scientific and Clinical Advisory Boards to invent and develop new therapies for patients.”
